Status:
COMPLETED
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
Lead Sponsor:
Nalagenetics Pte Ltd
Conditions:
ER+ Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CY...
Eligibility Criteria
Inclusion
- Diagnosed with ER+ breast cancer
- Have taken tamoxifen daily for at least 2 months
Exclusion
- Have not taken tamoxifen daily for at least 2 months
Key Trial Info
Start Date :
September 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT04312347
Start Date
September 6 2019
End Date
June 30 2021
Last Update
August 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MRCCC Siloam Hospital Semanggi
Jakarta, DKI Jakarta, Indonesia, 12930